TiumBio Officially Invited to Participate in JP Morgan Healthcare Conference
Tium Bio announced on the 5th that it has been officially invited to participate in the '2024 JP Morgan Healthcare Conference.'
The JP Morgan Healthcare Conference (JPMHC), held from the 8th to the 11th in San Francisco, California, USA, is known as the world's largest pharmaceutical and biotech investment conference. It is expected to gather 600 companies and over 8,000 investment industry professionals.
Tium Bio's CEO Kim Hoon-taek and Head of Business Development Yoon Seok-won will visit the site to engage with global big pharma companies. They will seek partners for new drugs such as 'Marigoldix (TU2670),' a uterine fibroids and endometriosis treatment currently in the final stages of clinical trials, and 'TU2218,' an oral immuno-oncology drug. Additionally, they plan to attend the 'Bio Partnering at JPM Week,' an event linked to JPMHC, to expand business development opportunities with potential partners.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Domestic Banks' Q1 Net Profit at 6.7 Trillion Won...Down 3.9%
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Kim Hoon-taek, CEO of Tium Bio, said, “Starting well with JPMHC, we will do our best to deliver successful clinical results and business development achievements this year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.